Home › Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
 

Keywords :   


Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection

2013-01-07 14:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDAs review to be completed in the first half of 2013. Language:  English Contact HTML:  MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: application drug acceptance injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Public Advisory Number 20A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07Atlantic Tropical Weather Outlook
03.07Genesus to restructure with Canada ZF Investments
03.07Global trade, domestic policy: What's at stake for pork industry
03.07Over 20,000 Tesco staff to split 30m from share schemes
03.07Ex-Post Office chair denies hiding key Horizon report
More »